Which has higher earnings & valuation, CTEV or CERT?

Certara has lower revenue, but higher earnings than Claritev. Certara is trading at a lower price-to-earnings ratio than Claritev, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Claritev $965.41M 0.52 -$284.28M -$17.01 N/A Certara $418.84M 3.22 -$1.60M -$0.45 N/A

Is CTEV or CERT more profitable?

Certara has a net margin of -16.75% compared to Claritev's net margin of -28.46%. Certara's return on equity of 3.86% beat Claritev's return on equity. Company Net Margins Return on Equity Return on Assets Claritev -28.46% N/A -5.76% Certara -16.75% 3.86% 2.65%

Does the media refer more to CTEV or CERT?

In the previous week, Claritev had 7 more articles in the media than Certara. MarketBeat recorded 8 mentions for Claritev and 1 mentions for Certara. Claritev's average media sentiment score of 0.52 beat Certara's score of -0.38 indicating that Claritev is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Claritev 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Certara 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, CTEV or GDRX?

GoodRx has lower revenue, but higher earnings than Claritev. Claritev is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Claritev $965.41M 0.52 -$284.28M -$17.01 N/A GoodRx $796.85M 1.48 $30.44M $0.04 86.00

Is CTEV or GDRX more profitable?

GoodRx has a net margin of 2.07% compared to Claritev's net margin of -28.46%. GoodRx's return on equity of 7.22% beat Claritev's return on equity. Company Net Margins Return on Equity Return on Assets Claritev -28.46% N/A -5.76% GoodRx 2.07% 7.22% 2.53%

Which has better valuation & earnings, CTEV or TDOC?

Teladoc Health has higher revenue and earnings than Claritev. Teladoc Health is trading at a lower price-to-earnings ratio than Claritev, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Claritev $965.41M 0.52 -$284.28M -$17.01 N/A Teladoc Health $2.53B 0.46 -$200.32M -$0.99 N/A

Does the media favor CTEV or TDOC?

In the previous week, Teladoc Health had 3 more articles in the media than Claritev. MarketBeat recorded 11 mentions for Teladoc Health and 8 mentions for Claritev. Claritev's average media sentiment score of 0.52 beat Teladoc Health's score of 0.11 indicating that Claritev is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Claritev 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teladoc Health 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, CTEV or HSTM?

HealthStream has lower revenue, but higher earnings than Claritev. Claritev is trading at a lower price-to-earnings ratio than HealthStream, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Claritev $965.41M 0.52 -$284.28M -$17.01 N/A HealthStream $304.06M 2.79 $18.34M $0.72 40.29

Does the media favor CTEV or HSTM?

In the previous week, Claritev had 6 more articles in the media than HealthStream. MarketBeat recorded 8 mentions for Claritev and 2 mentions for HealthStream. Claritev's average media sentiment score of 0.52 beat HealthStream's score of 0.23 indicating that Claritev is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Claritev 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HealthStream 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CTEV or SOPH?

In the previous week, Claritev had 4 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 8 mentions for Claritev and 4 mentions for SOPHiA GENETICS. Claritev's average media sentiment score of 0.52 beat SOPHiA GENETICS's score of -0.05 indicating that Claritev is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Claritev 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SOPHiA GENETICS 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Claritev (CTEV) Competitors

$29.48 -2.14 (-6.77%)

As of 09/22/2026 03:58 PM Eastern

Compare

CTEV vs. CERT, GDRX, TDOC, HSTM, and SOPH

Should you buy Claritev stock or one of its competitors? Claritev's main competitors and comparable companies include Certara (CERT), GoodRx (GDRX), Teladoc Health (TDOC), HealthStream (HSTM), and SOPHiA GENETICS (SOPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Claritev compare to Certara?

Claritev (NYSE:CTEV) and Certara (NASDAQ:CERT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Claritev has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Certara has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Certara has a net margin of -16.75% compared to Claritev's net margin of -28.46%. Certara's return on equity of 3.86% beat Claritev's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Claritev	-28.46%	N/A	-5.76%
Certara	-16.75%	3.86%	2.65%

87.2% of Claritev shares are owned by institutional investors. Comparatively, 74.0% of Certara shares are owned by institutional investors. 7.4% of Claritev shares are owned by company insiders. Comparatively, 1.1% of Certara shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Certara has lower revenue, but higher earnings than Claritev. Certara is trading at a lower price-to-earnings ratio than Claritev, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Claritev	$965.41M	0.52	-$284.28M	-$17.01	N/A
Certara	$418.84M	3.22	-$1.60M	-$0.45	N/A

Claritev currently has a consensus target price of $44.83, indicating a potential upside of 52.08%. Certara has a consensus target price of $8.28, indicating a potential downside of 6.25%. Given Claritev's stronger consensus rating and higher possible upside, equities analysts clearly believe Claritev is more favorable than Certara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Claritev	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Certara	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45

In the previous week, Claritev had 7 more articles in the media than Certara. MarketBeat recorded 8 mentions for Claritev and 1 mentions for Certara. Claritev's average media sentiment score of 0.52 beat Certara's score of -0.38 indicating that Claritev is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Claritev	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Certara	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Claritev beats Certara on 9 of the 17 factors compared between the two stocks.

How does Claritev compare to GoodRx?

Claritev (NYSE:CTEV) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Claritev has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, GoodRx has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

GoodRx has lower revenue, but higher earnings than Claritev. Claritev is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Claritev	$965.41M	0.52	-$284.28M	-$17.01	N/A
GoodRx	$796.85M	1.48	$30.44M	$0.04	86.00

87.2% of Claritev shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 7.4% of Claritev shares are owned by company insiders. Comparatively, 5.9% of GoodRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Claritev had 8 more articles in the media than GoodRx. MarketBeat recorded 8 mentions for Claritev and 0 mentions for GoodRx. Claritev's average media sentiment score of 0.52 beat GoodRx's score of 0.00 indicating that Claritev is being referred to more favorably in the media.

Company	Overall Sentiment
Claritev	Positive
GoodRx	Neutral

Claritev currently has a consensus target price of $44.83, suggesting a potential upside of 52.08%. GoodRx has a consensus target price of $4.23, suggesting a potential upside of 22.89%. Given Claritev's stronger consensus rating and higher probable upside, equities analysts plainly believe Claritev is more favorable than GoodRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Claritev	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08

GoodRx has a net margin of 2.07% compared to Claritev's net margin of -28.46%. GoodRx's return on equity of 7.22% beat Claritev's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Claritev	-28.46%	N/A	-5.76%
GoodRx	2.07%	7.22%	2.53%

Summary

Claritev and GoodRx tied by winning 8 of the 16 factors compared between the two stocks.

How does Claritev compare to Teladoc Health?

Claritev (NYSE:CTEV) and Teladoc Health (NYSE:TDOC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Claritev has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Teladoc Health has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

Teladoc Health has a net margin of -7.13% compared to Claritev's net margin of -28.46%. Claritev's return on equity of 0.00% beat Teladoc Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Claritev	-28.46%	N/A	-5.76%
Teladoc Health	-7.13%	-12.15%	-5.83%

Claritev currently has a consensus target price of $44.83, indicating a potential upside of 52.08%. Teladoc Health has a consensus target price of $7.54, indicating a potential upside of 18.82%. Given Claritev's stronger consensus rating and higher probable upside, equities analysts plainly believe Claritev is more favorable than Teladoc Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Claritev	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Teladoc Health	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25

Teladoc Health has higher revenue and earnings than Claritev. Teladoc Health is trading at a lower price-to-earnings ratio than Claritev, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Claritev	$965.41M	0.52	-$284.28M	-$17.01	N/A
Teladoc Health	$2.53B	0.46	-$200.32M	-$0.99	N/A

In the previous week, Teladoc Health had 3 more articles in the media than Claritev. MarketBeat recorded 11 mentions for Teladoc Health and 8 mentions for Claritev. Claritev's average media sentiment score of 0.52 beat Teladoc Health's score of 0.11 indicating that Claritev is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Claritev	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teladoc Health	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

87.2% of Claritev shares are owned by institutional investors. Comparatively, 76.8% of Teladoc Health shares are owned by institutional investors. 7.4% of Claritev shares are owned by company insiders. Comparatively, 0.7% of Teladoc Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Claritev beats Teladoc Health on 10 of the 16 factors compared between the two stocks.

How does Claritev compare to HealthStream?

Claritev (NYSE:CTEV) and HealthStream (NASDAQ:HSTM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

87.2% of Claritev shares are owned by institutional investors. Comparatively, 69.6% of HealthStream shares are owned by institutional investors. 7.4% of Claritev shares are owned by company insiders. Comparatively, 20.4% of HealthStream shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

HealthStream has a net margin of 6.60% compared to Claritev's net margin of -28.46%. HealthStream's return on equity of 6.81% beat Claritev's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Claritev	-28.46%	N/A	-5.76%
HealthStream	6.60%	6.81%	4.64%

HealthStream has lower revenue, but higher earnings than Claritev. Claritev is trading at a lower price-to-earnings ratio than HealthStream, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Claritev	$965.41M	0.52	-$284.28M	-$17.01	N/A
HealthStream	$304.06M	2.79	$18.34M	$0.72	40.29

In the previous week, Claritev had 6 more articles in the media than HealthStream. MarketBeat recorded 8 mentions for Claritev and 2 mentions for HealthStream. Claritev's average media sentiment score of 0.52 beat HealthStream's score of 0.23 indicating that Claritev is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Claritev	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthStream	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Claritev currently has a consensus target price of $44.83, indicating a potential upside of 52.08%. HealthStream has a consensus target price of $27.00, indicating a potential downside of 6.93%. Given Claritev's stronger consensus rating and higher possible upside, equities research analysts clearly believe Claritev is more favorable than HealthStream.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Claritev	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Claritev has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, HealthStream has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Summary

Claritev and HealthStream tied by winning 8 of the 16 factors compared between the two stocks.

How does Claritev compare to SOPHiA GENETICS?

Claritev (NYSE:CTEV) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

SOPHiA GENETICS has lower revenue, but higher earnings than Claritev. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Claritev, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Claritev	$965.41M	0.52	-$284.28M	-$17.01	N/A
SOPHiA GENETICS	$77.27M	8.76	-$79M	-$1.15	N/A

Claritev currently has a consensus target price of $44.83, suggesting a potential upside of 52.08%. SOPHiA GENETICS has a consensus target price of $10.00, suggesting a potential upside of 23.92%. Given Claritev's stronger consensus rating and higher probable upside, research analysts plainly believe Claritev is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Claritev	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
SOPHiA GENETICS	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Claritev had 4 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 8 mentions for Claritev and 4 mentions for SOPHiA GENETICS. Claritev's average media sentiment score of 0.52 beat SOPHiA GENETICS's score of -0.05 indicating that Claritev is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Claritev	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SOPHiA GENETICS	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Claritev has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

87.2% of Claritev shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 7.4% of Claritev shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Claritev has a net margin of -28.46% compared to SOPHiA GENETICS's net margin of -93.86%. Claritev's return on equity of 0.00% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Claritev	-28.46%	N/A	-5.76%
SOPHiA GENETICS	-93.86%	-132.47%	-45.97%

Summary

Claritev beats SOPHiA GENETICS on 12 of the 16 factors compared between the two stocks.

Get Claritev News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTEV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTEV vs. The Competition

Export

Metric	Claritev	Healthcare Technology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$535.88M	$1.72B	$7.27B	$23.14B
Dividend Yield	N/A	3.89%	2.53%	3.62%
P/E Ratio	-1.73	21.05	274.31	28.40
Price / Sales	0.52	89.18	639.21	21.42
Price / Cash	2.05	31.68	76.31	39.12
Price / Book	-2.92	6.22	10.69	4.71
Net Income	-$284.28M	-$18.66M	$3.49B	$1.07B
7 Day Performance	-12.39%	1.62%	2.58%	0.58%
1 Month Performance	-20.39%	2.00%	-1.80%	-3.43%
1 Year Performance	-42.76%	-16.43%	18.64%	8.48%

Claritev Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTEV Claritev	3.4101 of 5 stars	$29.48 -6.8%	$44.83 +52.1%	-43.0%	$535.88M	$965.41M	N/A	3,000	Analyst Forecast Insider Trade Gap Up
CERT Certara	1.1134 of 5 stars	$8.42 -1.9%	$8.28 -1.7%	-24.4%	$1.31B	$418.84M	N/A	1,576	High Trading Volume
GDRX GoodRx	4.0729 of 5 stars	$3.38 -0.6%	$4.23 +25.1%	-15.5%	$1.16B	$796.85M	84.52	697	Positive News
TDOC Teladoc Health	2.5688 of 5 stars	$6.32 +0.6%	$7.54 +19.3%	-22.7%	$1.14B	$2.53B	N/A	5,600	Positive News
HSTM HealthStream	2.4492 of 5 stars	$29.23 +0.1%	$27.00 -7.6%	-1.0%	$852.79M	$304.06M	40.60	1,160	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CTEV) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Claritev (CTEV) Competitors

CTEV vs. CERT, GDRX, TDOC, HSTM, and SOPH

How does Claritev compare to Certara?

Summary

How does Claritev compare to GoodRx?

Summary

How does Claritev compare to Teladoc Health?

Summary

How does Claritev compare to HealthStream?

Summary

How does Claritev compare to SOPHiA GENETICS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTEV vs. The Competition

Claritev Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Claritev (CTEV) Competitors

CTEV vs. CERT, GDRX, TDOC, HSTM, and SOPH

How does Claritev compare to Certara?

Which has more volatility & risk, CTEV or CERT?

Is CTEV or CERT more profitable?

Do institutionals and insiders believe in CTEV or CERT?

Which has higher earnings & valuation, CTEV or CERT?

Do analysts recommend CTEV or CERT?

Does the media refer more to CTEV or CERT?

Summary

How does Claritev compare to GoodRx?

Which has more volatility and risk, CTEV or GDRX?

Which has higher valuation and earnings, CTEV or GDRX?

Do institutionals & insiders have more ownership in CTEV or GDRX?

Does the media favor CTEV or GDRX?

Do analysts recommend CTEV or GDRX?

Is CTEV or GDRX more profitable?

Summary

How does Claritev compare to Teladoc Health?

Which has more risk and volatility, CTEV or TDOC?

Is CTEV or TDOC more profitable?

Do analysts rate CTEV or TDOC?

Which has better valuation & earnings, CTEV or TDOC?

Does the media favor CTEV or TDOC?

Do institutionals & insiders hold more shares of CTEV or TDOC?

Summary

How does Claritev compare to HealthStream?

Do insiders and institutionals believe in CTEV or HSTM?

Is CTEV or HSTM more profitable?

Which has preferable valuation and earnings, CTEV or HSTM?

Does the media favor CTEV or HSTM?

Do analysts rate CTEV or HSTM?

Which has more risk & volatility, CTEV or HSTM?

Summary

How does Claritev compare to SOPHiA GENETICS?

Which has higher earnings & valuation, CTEV or SOPH?

Do analysts recommend CTEV or SOPH?

Does the media favor CTEV or SOPH?

Which has more risk and volatility, CTEV or SOPH?

Do insiders & institutionals believe in CTEV or SOPH?

Is CTEV or SOPH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTEV vs. The Competition

Claritev Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools